Takeda sees China as 2nd-biggest drug market
Print Edition
JAPAN’S largest pharmaceutical company Takeda aims to build China into its second-largest market within 10 years by introducing new products more quickly in the country.
Takeda plans to unveil at least three to four innovative drugs in China in the next five years to broaden its pipeline of drugs to treat diabetes and tumors, Giles Platford, president of emerging markets unit at Takeda, said in an interview with Shanghai Daily.
China is now Takeda’s fourth-largest market by sales. The company’s global revenue was US$16.9 billion in the financial year ended on March 31, this year. The country is expected to become the world’s second-largest pharmaceutical market next year.
Currently, Takeda’s sales in China mainly come from off-patent generic drugs but it will step up efforts to launch more innovative drugs to drive sales in the country, Platford said.
Takeda operates the Shanghai Development Center as a clinical trial facility for products that have been researched and developed outside China for approval by China’s Food and Drug Administration.
Within a few months Takeda will also unveil a logistics center in Taizhou in Jiangsu Province which will distribute Takeda drugs imported from Europe and Japan.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 娌狪CP璇侊細娌狪CP澶05050403鍙-1
- |
- 浜掕仈缃戞柊闂讳俊鎭湇鍔¤鍙瘉锛31120180004
- |
- 缃戠粶瑙嗗惉璁稿彲璇侊細0909346
- |
- 骞挎挱鐢佃鑺傜洰鍒朵綔璁稿彲璇侊細娌瓧绗354鍙
- |
- 澧炲肩數淇′笟鍔＄粡钀ヨ鍙瘉锛氭勃B2-20120012
Copyright 漏 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
